Welcome to our dedicated page for MorphoSys American Depositary Shares news (Ticker: $MOR), a resource for investors and traders seeking the latest updates and insights on MorphoSys American Depositary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MorphoSys American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MorphoSys American Depositary Shares's position in the market.
MorphoSys AG reported its first-quarter 2024 financial results, including a proposed acquisition by Novartis, receipt of antitrust approvals, sale of tafasitamab rights to Incyte, and upcoming medical conference presentations. The company's financials showed an increase in group revenues, cost of sales, research and development expenses, and general and administrative expenses. The operating loss and consolidated net loss also increased significantly. Full-year 2024 financial guidance was revoked due to the sale of tafasitamab. MorphoSys expects R&D expenses of €170-185 million and SG&A expenses of €90-105 million for the year.
